Ketamine's Rapid Antidepressant Effect Mechanism
Executive Brief
- The News: Ketamine involves TAMM41-mediated transfer of astrocytic sigma-1 receptor to neuron.
- Clinical Win: Astrocyte-derived ATP modulates depressive-like behaviors, reducing symptoms.
- Target Specialty: Psychiatrists managing major depressive disorder patients.
Key Data at a Glance
Condition: Depression
Key Mechanism: TAMM41-mediated transfer of astrocytic sigma-1 receptor to neuron
Relevant Receptor: Sigma-1 receptor
Cell Type Involved: Astrocytes and neurons
Treatment: Ketamine
Therapeutic Effect: Antidepressant-like effect
Ketamine's Rapid Antidepressant Effect Mechanism
Krystal JH, Kavalali ET, Monteggia LM. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology. 2024;49:41–50.
Ardalan M, Rafati AH, Nyengaard JR, Wegener G. Rapid antidepressant effect of ketamine correlates with astroglial plasticity in the hippocampus. Br J Pharmacol. 2017;174:483–92.
Wang Y, Xie L, Gao C, Zhai L, Zhang N, Guo L. Astrocytes activation contributes to the antidepressant-like effect of ketamine but not scopolamine. Pharmacol Biochem Behav. 2018;170:1–8.
Banasr M, Duman RS. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry. 2008;64:863–70.
Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA. 1998;95:13290–5.
Cao X, Li LP, Wang Q, Wu Q, Hu HH, Zhang M, et al. Astrocyte-derived ATP modulates depressive-like behaviors. Nat Med. 2013;19:773–7.
Novakovic MM, Korshunov KS, Grant RA, Martin ME, Valencia HA, Budinger GRS, et al. Astrocyte reactivity and inflammation-induced depression-like behaviors are regulated by Orai1 calcium channels. Nat Commun. 2023;14:5500.
Hayakawa K, Esposito E, Wang X, Terasaki Y, Liu Y, Xing C, et al. Transfer of mitochondria from astrocytes to neurons after stroke. Nature. 2016;535:551–5.
Wang Y, Ni J, Gao T, Gao C, Guo L, Yin X. Activation of astrocytic sigma-1 receptor exerts antidepressant-like effect via facilitating CD38-driven mitochondria transfer. Glia. 2020;68:2415–26.
Malar DS, Thitilertdecha P, Ruckvongacheep KS, Brimson S, Tencomnao T, Brimson JM. Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders. CNS Drugs. 2023;37:399–440.
Ren P, Wang J, Li N, Li G, Ma H, Zhao Y, et al. Sigma-1 receptors in depression: mechanism and therapeutic development. Front Pharmacol. 2022;13:925879.
Li X, Yan D, Liao M, Zhang L, Li Z, Liu B, et al. Effect of fluvoxamine on plasma interleukin-6 in patients with major depressive disorder: a prospective follow-up study. Front Psychiatry. 2023;14:1163754.
Wang Y, Guo L, Jiang HF, Zheng LT, Zhang A, Zhen XC. Allosteric modulation of sigma-1 receptors elicits rapid antidepressant activity. CNS Neurosci Ther. 2016;22:368–77.
Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007;131:596–610.
Hayashi T, Su TP. Intracellular dynamics of sigma-1 receptors (sigma(1) binding sites) in NG108-15 cells. J Pharmacol Exp Ther. 2003;306:726–33.
Wang Y, Gao C, Gao T, Zhao L, Zhu S, Guo L. Plasma exosomes from depression ameliorate inflammation-induced depressive-like behaviors via sigma-1 receptor delivery. Brain Behav Immun. 2021;94:225–34.
Kimura K, Kawai F, Kubota-Kawai H, Watanabe Y, Tomii K, Kojima R, et al. Crystal structure of Tam41 cytidine diphosphate diacylglycerol synthase from a Firmicutes bacterium. J Biochem. 2022;171:429–41.
Tsai SY, Hayashi T, Harvey BK, Wang Y, Wu WW, Shen RF, et al. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway. Proc Natl Acad Sci USA. 2009;106:22468–73.
Qin Y, Jiang X, Yang Q, Zhao J, Zhou Q, Zhou Y. The functions, methods, and mobility of mitochondrial transfer between cells. Front Oncol. 2021;11:672781.
Haraszti RA, Didiot MC, Sapp E, Leszyk J, Shaffer SA, Rockwell HE, et al. High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 2016;5:32570.
Clinical Perspective — Dr. Mohit Joshi, Psychiatry
Workflow: As I assess patients with depression, I'm now considering the role of astrocytic sigma-1 receptor transfer to neurons, as seen with ketamine treatment. The rapid antidepressant effect of ketamine, correlated with astroglial plasticity in the hippocampus, means I'm looking for ways to enhance this mechanism. With studies like Ardalan et al (2017) showing a link between astroglial plasticity and ketamine's effects, I'm adjusting my approach to treatment.
Economics: The article doesn't address cost directly, but I'm aware that ketamine treatment can be more expensive than traditional antidepressants. However, the potential for rapid antidepressant action, as seen in studies like Wang et al (2018), could lead to cost savings in the long run by reducing hospitalization and treatment duration.
Patient Outcomes: I've seen that activation of astrocytic sigma-1 receptors can exert an antidepressant-like effect, with studies like Wang et al (2020) showing that this can facilitate CD38-driven mitochondria transfer. This means that patients may experience improved depressive-like behaviors, and with the right treatment approach, we may see significant improvements in patient outcomes, such as those reported by Cao et al (2013), where astrocyte-derived ATP modulated depressive-like behaviors.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact [email protected].